Synthetic RNA kit business Synthego has raised $41 million to step up its efforts to make CRISPR gene editing easier and more accurate.

NeRRe Therapeutics has raised £23 million in a Series B backed by new investors Fountain Healthcare Partners, Forbion Capital Partners and OrbiMed.

After raising a $285 million special op fund last month, and changing its name from Flagship Ventures to Flagship Pioneering, the VC has also now announced it…

RaNA Therapeutics has acquired Shire’s mRNA therapy platform, originally developed by its MRT employees, who have also now joined RaNA as part of the deal.

Ascletis has raised $100 million in a second-round financing as it prepares for the launch of its first commercial product.

Biotech, like all other industries and the British public, is no closer to knowing what life will look like post-Brexit than it was on June 24.

It’s the time of year for editors to look ahead and attempt to predict, based on the patterns of the past 12 months, what the next trip around the sun will…

This year will not go down as a classic for biotech IPOs; in fact, it’s been pretty dismal, with a report by Renaissance Capital out in the summer showing that…

Bristol-Myers Squibb has signed a new preclinical deal with British biotech PsiOxus to work on its oncolytic virus NG-348 in a deal that could be worth just…

Venture Capital